Laxmikant A. Gharat - Concepedia

Author

Laxmikant A. Gharat

Glenmark Pharmaceuticals (India)

Also Known As

L. A. GHARAT, L. Gharat, L.A. Gharat, Laxmikant A Gharat, Laxmikant A. Gharat, Laxmikant Gharat

Publications

589

Citations

H-Index

Concepts

All Affiliations

Glenmark Pharmaceuticals (India)Monmouth Medical Center Andhra University Universidade do Porto Hospital de São João

About

Laxmikant A. Gharat is an author at Glenmark Pharmaceuticals (India) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	300
2	Natural Sciences	4	4	80
3	Health Sciences	3	3	110
4	Biochemistry	3	3	91
5	Engineering	1	1	39

Laxmikant A. Gharat

Publications

536

Citations

H-Index

Page 1

	Year	Citations
GRC-6211, a New Oral Specific TRPV1 Antagonist, Decreases Bladder Overactivity and Noxious Bladder Input in Cystitis Animal Models Ana Charrua, Célia Duarte Cruz, Shridhar Narayanan, The Journal of Urology	2008	103
Screening TRPV1 antagonists for the treatment of pain: lessons learned over a decade József Lázár, Laxmikant A. Gharat, Neelima Khairathkar-Joshi, Expert Opinion on Drug Discovery	2009	49
Synthesis and evaluation of some novel isochroman carboxylic acid derivatives as potential anti-diabetic agents Y. Rajendra Prasad, Laxmikant A. Gharat, Abraham Thomas, European Journal of Medicinal Chemistry Derivative (Chemistry)MedicineDiabetesPharmacologyPotential Anti-diabetic Agents	2009	43
Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists Laxmikant A. Gharat, A Szállaśi Expert Opinion on Therapeutic Patents Pain TherapyPain DisordersPain MedicineImmunologyMolecular Pain	2008	39
Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents Y. Rajendra Prasad, Laxmikant A. Gharat, Abraham Thomas, European Journal of Medicinal Chemistry Medicinal ChemistryCarboxylic AcidsEngineeringDerivative (Chemistry)Organic Chemistry	2010	39
Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist André Silva, Ana Charrua, Célia Duarte Cruz, Autonomic Neuroscience Health SciencesMedicinePhysiologyNeuropathic PainNeuroscience	2011	37
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model Abhisek Banerjee, S. D. Patil, Mahesh Y. Pawar, Bioorganic & Medicinal Chemistry Letters Disease ModelMedicineRational Drug DesignParkinson ’Pharmacological Agent	2012	34
Medicinal chemistry of the vanilloid (Capsaicin) TRPV1 receptor: current knowledge and future perspectives Laxmikant A. Gharat, A Szállaśi Drug Development Research Pharmaceutical SciencePain DisordersFuture PerspectivesTrpv1 Receptor ActivityPain Medicine	2007	34
Development of 2-aryl substituted quinazolin-4(3H)-one, pyrido[4,3-d]pyrimidin-4(3H)-one and pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as microsomal prostaglandin E2 synthase-1 inhibitors Abhisek Banerjee, Mahesh Y. Pawar, S. D. Patil, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesDrug Development	2014	31
Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors Abhisek Banerjee, Lakshminarayana Narayana, Firoj A. Raje, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBioorganic ChemistryBiochemistryPhosphodiesterase 10ANatural Sciences	2013	26

Page 1